BARCELONA — Final, five-year results from the SYNTAX trial comparing CABG surgery and PCI with a drug-eluting stent (DES) in patients with complex coronary disease confirm the message that started to ...
NATICK, Mass. and WASHINGTON, Oct. 14 BostonScientific Corporation (NYSE: BSX) today announced 12-month left main andthree-vessel disease subset data from its landmark SYNTAX trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback